ALGS News & Events

Aligos Therapeutics announced positive data from two presentations at the Conference on Retroviruses and Opportunistic Infections, CROI, being held February 22 - 25, 2026 in Denver, Colorado. The pevifoscorvir sodium presentation highlights the Phase 1 monotherapy study of pevifoscorvir sodium, a potent CAM-E under development for the treatment of chronic hepatitis B virus infection. Additionally, the ALG-097558 presentation showcases data from participants with hepatic and renal impairment. "We are pleased to continue showcasing the best/first-in-class pevifoscorvir sodium data from the Phase 1 study in participants with chronic HBV infection," said Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and CEO of Aligos Therapeutics. "Additionally, we continue to move our COVID program forward with grants from government agencies and are pleased to show some of this important clinical work at CROI this year."

Aligos Therapeutics announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 81,100 shares of the Company's stock to newly hired employees on January 29, 2026, in connection with the commencement of employment.

Aligos Therapeutics announced a progress update for the Phase 2 B-SUPREME study of pevifoscorvir sodium in subjects with chronic hepatitis B virus, HBV, infection. The first protocol defined interim analysis includes approximately 60% HBeAg- participants that complete 12 weeks of the treatment period. This enrollment milestone occurred in Q4 2025. In addition, the planned enrollment of this cohort of 60 HBeAg- participants completed in January 2026. The first interim analysis is expected to occur in the first half of 2026. A second protocol defined interim analysis is planned when approximately 50% HBeAg+ participants complete 24 weeks of the treatment period. This enrollment milestone occurred in January 2026. This interim analysis is expected to occur in the second half of 2026.

Hardean Achneck, MD resigned from his position as Executive Vice President, Chief Medical Officer.